Phase III trial

Showing 7 posts of 7 posts found.

Pharnext CMT drug shows positive Phase III results

April 29, 2021
CMT, Charcot-Marie-Tooth Disease, Phase III trial, pharma, pharma news, pharnext

Pharnext SA’s PXT3003 treatment for patients with Charcot-Marie-Tooth Disease (CMT) has shown positive interim results in its ongoing Phase III …

GSK building

GSK & Vir’s COVID-19 treatment shows 85% efficacy in Phase III trial

March 29, 2021
Sales and Marketing COVID-19, GSK, Phase III trial, covid-19 treatment, vir

GSK and Vir Biotechnology have submitted an Emergency Use Authorization request to the FDA for their VIR-7831 therapy for the …

Pfizer and Myovant’s menstrual blood loss treatment reports 78% effectiveness

March 24, 2021
Research and Development Myovant, Pfizer, Phase III trial, fibroids, uterine fibroids

Pfizer and Myovant Science’s relugolix treatment to reduce menstrual blood loss in women with uterine fibroids has shown promising results …

Roche's building

Roche’s Huntington’s disease treatment disappoints in Phase III trial

March 23, 2021
Manufacturing and Production Huntington's, Phase III trial, Roche, huntington's disease, tominersen

Roche has discontinued dosing in a Phase III trial of its tominersen treatment for Huntington’s disease, following discouraging initial data.

Eli Lilly building

Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial

March 17, 2021
Research and Development Eli Lilly, Phase III trial, lilly, mirikizumab, ulcerative colitis

Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and all key secondary endpoints in …

AstraZeneca to discontinue trial for heart disease drug Epanova

January 13, 2020
Sales and Marketing AstraZeneca, Phase II Trial, Phase III trial, heart disease, triglycerides

AstraZeneca expects a $100 million writedown for its heart disease drug Epanova, as it discontinues its late stage trial. This …

amgen_hq

Positive Phase III results for Amgen’s Repatha for coronary artery disease

September 21, 2016
Research and Development Amgen, Phase III trial, Repatha

Amgen has announced that its monoclonal antibody Repatha (evolocumab) achieved positive Phase III results for the treatment of coronary artery …

Latest content